NCT00163891

Brief Summary

Chest infection is a common complication following lung transplant (LTx). Chest physiotherapy is widely accepted as an integral part of the management of chest infections, however there is no evidence available regarding the effectiveness of chest physiotherapy regimes for LTx recipients. There is no consensus regarding whether LTx recipients should be instructed to perform regular daily chest physiotherapy routines regardless of the presence of lung secretions (ie prophylatically) because of the changes in mucus clearance bought about by lung transplant, or only when they have a chest infection. Some clinicians believe that a prophylactic regimen may be beneficial. This research will compare two chest physiotherapy treatment regimens - our current practice of chest physiotherapy during chest infections only (Treatment A) with an independently performed daily chest physiotherapy regimen regardless of the presence of a chest infection (Treatment B). From this research, we aim to develop evidence-based treatment guidelines.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2003

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 14, 2005

Completed
Last Updated

October 4, 2006

Status Verified

September 1, 2005

First QC Date

September 12, 2005

Last Update Submit

October 3, 2006

Conditions

Keywords

Respiratory TherapyPostoperative CareTreatment Outcome

Outcome Measures

Primary Outcomes (7)

  • Lung function

  • Chest radiographic score -Brasfield Score

  • Bronchoscopy score

  • Days in hospital due to chest infection

  • Antibiotic use

  • Quality of Life - SF-36 Health Survey

  • Functional exercise capacity - 6 minute walk test

Secondary Outcomes (2)

  • Patient adherence to the alternative protocols

  • Patient satisfaction with the alternative protocols.

Interventions

Eligibility Criteria

Age16 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All lung transplant recipients treated at The Alfred will be invited to participate in the study at three weeks following lung transplantation.

You may not qualify if:

  • ventilator dependent
  • tracheostomy insitu
  • pneumothorax
  • major myopathy
  • oxygen requirement of greater than 4 litres per minute
  • or any condition that prevents them from performing PEP mask chest physiotherapy at the time of recruitment to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Alfred Hospital

Melbourne, Victoria, 3004, Australia

Location

Study Officials

  • Michael Bailey, M Stat PhD

    Dept of Epidemiology & Preventative Medicine Monash University

    PRINCIPAL INVESTIGATOR
  • Prue E Munro, B Physio GradDip HealthMan

    The Alfred

    PRINCIPAL INVESTIGATOR
  • Brenda B Button, DPhysio PhD

    The Alfred

    PRINCIPAL INVESTIGATOR
  • Samantha Ellis

    The Alfred

    PRINCIPAL INVESTIGATOR
  • Greg I Snell, MBBS FRACP

    The Alfred

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 14, 2005

Study Start

September 1, 2003

Last Updated

October 4, 2006

Record last verified: 2005-09

Locations